module: m-hero-images-tall
Kymera_Images_Homepage_Hero

Breakthrough Medicines

Catalyzed by Protein Degradation

module: m-hero-images-tall (with badge)
Kymera_Images_Homepage_Hero

Breakthrough Medicines

Catalyzed by Protein Degradation

Kymera Therapeutics Announces Second Quarter 2023 Financial Results

module: m-hero-video

module: m-hero-images-short
Kymera_Images_Our-Company_Hero
module: m-hero-images-bio
"I am ambitious, focused and confident"
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum.At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum.
Kymera_Images_Leadership_Headshot_Nello-Mainolfi-PhD
module: m-image-block-1
Kymera_Images_Homepage_CTA_Our-Team
Kymera_Images-Mobile_Homepage_CTA_Our-Team
Our Team is Growing

Kymera is building a fully integrated medicines company to redefine disease treatment paradigms. Come work with us to shape the future of medicine.

module: m-image-block-1-cards
Kymera_Images_Leadership_CTA_Our-Leadership
Our Leadership is Driving the Field Forward

Kymera’s team is catalyzing progress in the science of TPD with key publications and presentations that unlock insights and showcase our findings.

November 1, 2023
Targeted Protein Degradation Mechanisms

Zhang, Y., Loh, C., Chen, J., & Mainolfi, N.

November 1, 2023
Targeted Protein Degradation Mechanisms

Zhang, Y., Loh, C., Chen, J., & Mainolfi, N.

November 1, 2023
Targeted Protein Degradation Mechanisms

Zhang, Y., Loh, C., Chen, J., & Mainolfi, N.

module: m-image-block-2
Kymera_Images_Our-Company_Full-Bleed

A Powerful Strategy that Puts Patients First

We tackle challenges and push the envelope on behalf of patients every day, pursuing new approaches to revolutionize disease treatment.

Learn More About Our Approach

module: m-image-block-3
Kymera_Images_Reinventing-Med_Block-Patient
A Powerful Strategy that Puts Patients First

We push boundaries with an incredible sense of urgency, knowing patients are waiting for our therapies and that every week, every day, and every hour counts. We tackle challenges such as traditionally “undruggable” disease-causing proteins, pursuing new approaches to revolutionize disease treatment and find solutions for patients.

module: m-image-block-4
Our Impact is Greater Together

Just like chimeric molecules combine two or more components to create a powerful and innovative therapeutic opportunity, together, we are greater than the sum of our parts.

We welcome like-minded pioneers to join us on our extraordinary journey as we create a culture where diverse perspectives are invited, and collaboration is celebrated—all in service of our goal to revolutionize medicine and change patients’ lives.

Our Impact is Greater Together

Just like chimeric molecules combine two or more components to create a powerful and innovative therapeutic opportunity, together, we are greater than the sum of our parts.

We welcome like-minded pioneers to join us on our extraordinary journey as we create a culture where diverse perspectives are invited, and collaboration is celebrated—all in service of our goal to revolutionize medicine and change patients’ lives.

module: m-image-block-5
Kymera_Images_Homepage_Block-Patient
Revolutionizing Medicine

Targeted protein degradation is a disease-agnostic technology fundamentally changing our understanding of how drugs need to work and the diseases it’s possible to treat.

module: m-default-editor

This is the m-default-editor.

Sed posuere consectetur est at lobortis. Etiam porta sem malesuada magna mollis euismod. Cras justo odio, dapibus ac facilisis in, egestas eget quam. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum.

Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Nulla vitae elit libero, a pharetra augue. Nullam quis risus eget urna mollis ornare vel eu leo.

Praesent commodo cursus magna, vel scelerisque nisl consectetur et. Cras mattis consectetur purus sit amet fermentum. Donec id elit non mi porta gravida at eget metus. Nullam quis risus eget urna mollis ornare vel eu leo. Cras mattis consectetur purus sit amet fermentum. Praesent commodo cursus magna, vel scelerisque nisl consectetur et. Praesent commodo cursus magna, vel scelerisque nisl consectetur et. Maecenas faucibus mollis interdum. Donec id elit non mi porta gravida at eget metus. Etiam porta sem malesuada magna mollis euismod. Nullam quis risus eget urna mollis ornare vel eu leo. Vestibulum id ligula porta felis euismod semper. Vestibulum id ligula porta felis euismod semper.

module: m-text-block-header
OUR APPROACH

Pioneering Targeted Protein Degradation to Invent New Medicines

Targeted protein degradation (TPD) is a compelling modality that harnesses the cell’s existing machinery to identify and eradicate disease-causing proteins that cannot be addressed, or are poorly addressed, by other modalities, delivering a potentially transformative new way to fight disease and dramatically improve patients’ lives.

Better Degraders Built from the Ground Up
Kymera’s differentiated approach is being employed to build a pipeline of first-in-class programs and propel the field of protein degradation forward.
Better Degraders Built from the Ground Up
Kymera’s differentiated approach is being employed to build a pipeline of first-in-class programs and propel the field of protein degradation forward.
module: m-text-block-body
PIPELINE
Our First-in-Class Pipeline Combines Cutting-Edge Science with Patient Impact

Nulla vitae elit libero, a pharetra augue. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Nullam id dolor id nibh ultricies vehicula ut id elit. Vestibulum id ligula porta felis euismod semper.

Since our founding, we’ve built a preeminent discovery engine capable of identifying new drug candidates at an accelerated pace and delivering at least one new program every year, and we’re advancing a pipeline of high-value programs poised to change patient lives.

module: m-text-block-body (with logos)
Partnerships for Amplified Impact

We partner with leading global pharmaceutical companies to develop transformative therapies for the broadest possible patient populations.

sanofi-seeklogo.com

Our current partnership with Sanofi is enabling us to accelerate the path to broader clinical development and commercialization of our first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.

Learn More About Sanofi
sanofi-seeklogo.com

Our current partnership with Sanofi is enabling us to accelerate the path to broader clinical development and commercialization of our first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.

Learn More About Sanofi
module: m-text-block-body (with icon/text rows)
We Want to Hear from You

We’re looking for pioneers to join us on our journey to revolutionize medicine. If you embrace the opportunity to do things that haven’t been done before and want to help us build a company that aspires to change patient’s lives, we may be a good fit for you. You belong at Kymera if you are:

icon-microscope

Driven

You don’t shy away from challenges and are compelled by cutting-edge science with the potential to impact patients’ lives.

icon-group

Community-Oriented

You seek out meaningful connections, collaborations, and friendships in your work environment.

icon-heart

Authentic

You want to bring your authentic self to work and achieve your full potential.

module: m-text-block-stats
Company Stats

We partner with leading global pharmaceutical companies to develop transformative therapies for the broadest possible patient populations.

92%
OF STAFF ARE INVOLVED IN COMMUNITY OUTREACH
187
OF STAFF ARE INVOLVED IN COMMUNITY OUTREACH
~65
OF STAFF ARE INVOLVED IN COMMUNITY OUTREACH
341
OF STAFF ARE INVOLVED IN COMMUNITY OUTREACH
module: m-text-columns
Recent news
November 1, 2023
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
November 1, 2023
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
November 1, 2023
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
module: m-text-two-cols

Better Degraders Built from the Ground Up

Kymera’s differentiated approach is being employed to build a pipeline of first-in-class programs and propel the field of protein degradation forward.

Target Selection

We are focused on deploying our technology against disease targets in areas of significant patient need that can’t be meaningfully addressed by traditional medicines and where TPD is the only or the best way to elucidate the desired biology or clinical outcome. This approach includes tackling undruggable proteins and addressing broad pathways and nodes with strong genetic validation in immunology and oncology.

Platform

Kymera’s powerful drug discovery engine generates high-potential programs that are primed for clinical stage development. Designing degrader medicines involves engaging the components of the modality’s unique ternary complex formation (the E3 ligase, degrader molecule, and protein to be degraded) to enable the body to eliminate disease-causing proteins. We’ve created a toolbox of integrated approaches to accelerate the discovery and development of transformative degrader medicines, and utilize a comprehensive hit identification strategy of biophysical, biochemical, and biological methods, including high throughput screenings and cutting-edge technologies like cryogenic electron microscopy and X-ray crystallography. These capabilities enable us to study molecular structures and gain a full understanding of the biological mechanisms of proteins. In addition, we work to maximize the efficacy of each molecule by using quantitative proteomics techniques to match target proteins with the optimal E3 ligase from our library of over 600 unique options across different tissues and cell types.

Preclinical to Clinical Translation

Our rigorous preclinical work not only sets up our own molecules for clinical success, but is pushing the entire field forward by shedding light on the best ways to design degraders with optimized properties tailored not only to specific diseases, but also potentially targeted patient populations. We have generated and validated predictive models that reflect our deep knowledge and understanding of the interplay between targets and drug properties, driving optimization of drug disposition and in vitro and in vivo pharmacokinetic/pharmacodynamic relationships of our degraders across different tissue and cell types. We are also exploring and leading the development of adjacent technologies and next generation TPD strategies to further expand the range of targets for degrader therapies.

kymeratx_science-and-innovation_our-approach_target-selection
kymeratx_science-and-innovation_our-approach_platform
kymeratx_science-and-innovation_our-approach_preclinical-to-clinical-translation
module: m-flexible-columns
kymeratx_home_our-pipeline
Medicines that Work with Your Cells to Treat Disease

With this promising technology, we have the potential to overcome the inherent limitations of other modalities and can design medicines that address diseases that have long been out of reach, including those associated with undruggable and hard-to-target proteins. And because our molecules can run this same degradation process over and over, we can deliver therapies that potentially require less frequent dosing, which may result in an improved safety profile.

TPD therapies are the kind of big idea that’s upending traditional wisdom about how drugs need to work—and opening doors many people never thought possible.

Kymera_Images_Reinventing-Med_Block-Employee
Creating Treatments that Challenge What’s Possible

We’re building a fully integrated biopharmaceutical company focused on meaningfully improving patient care through our unique nexus of biology, proprietary chemistry, data science, and translational research approaches. Our programs address well-validated and high value disease targets and broader biological pathways in therapeutic areas affecting large numbers of patients, where TPD is the best or only option to transform the standard of care.

We strive to achieve what may have seemed impossible in solving critical health problems.

We advanced the first oral small molecule degrader into the clinic for immunological diseases, and we’re progressing degrader medicines in oncology that target undrugged or poorly drugged proteins to create new ways to fight cancer that can potentially treat both solid and liquid tumors.

We continue to drive our science forward and evolve TPD and adjacent technologies by employing cutting-edge computational and research tools to enhance our understanding of the fundamental biological mechanisms of disease to build a deep and broad pipeline.

module: m-carousel
module: m-tabs
Kymera_Images_Working-At-Kymera_Carousel-Static_Careers

Get More Out of Life

We strive to give our people and their families benefit offerings that go above and beyond the physical to support your emotional and financial wellbeing. We offer competitive programs that enable employees to better integrate work, family, and community in a healthy, meaningful way and make it easy for you to enjoy your journey at Kymera. These programs will ensure you are supported, create opportunities for growth, and better connect you to our Kymera community.

View Additional Benefits

Need a break? We’ve got you covered. With three office shutdowns, summer hours, and paid time off, we want to give you the flexibility and time you need to step away from your work when you need it most. Our teams also get energy from engaging in philanthropic efforts and interacting socially, and we create ongoing opportunities to give back to our community and do fun things together—everything from knitting clubs to pickleball!

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Nullam id dolor id nibh ultricies vehicula ut id elit. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus.

Donec id elit non mi porta gravida at eget metus. Nullam quis risus eget urna mollis ornare vel eu leo. Cras justo odio, dapibus ac facilisis in, egestas eget quam. Praesent commodo cursus magna, vel scelerisque nisl consectetur et. Aenean lacinia bibendum nulla sed consectetur. Etiam porta sem malesuada magna mollis euismod.

Donec sed odio dui. Nulla vitae elit libero, a pharetra augue. Maecenas sed diam eget risus varius blandit sit amet non magna. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Etiam porta sem malesuada magna mollis euismod. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit.

module: m-tabs-banner
module: m-tabs-leadership

Management Team

Kymera’s leadership are all dedicated innovators, each with decades of experience in drug discovery and development and company building.
Kymera_Images_Leadership_Headshot_Nello-Mainolfi-PhD
Nello Mainolfi, Ph.D.
Founder, President & CEO
Kymera_Images_Leadership_Headshot_Jeremy-Chadwick-PhD
Jeremy Chadwick, Ph.D.
Chief Operating Officer
Kymera_Images_Leadership_Headshot_Ellen-Chiniara-JD
Ellen Chiniara, JD
Chief Legal Officer and Corporate Secretary
Kymera_Images_Leadership_Headshot_Jared-Gollob-MD
Jared Gollob, MD
Chief Medical Officer
Kymera_Images_Leadership_Headshot_Bruce-Jacobs-CFA-MBA
Bruce Jacobs, CFA, MBA
Chief Financial Officer
Kymera_Images_Leadership_Headshot_Karen-Weisbach
Karen Weisbach
Head of People and Culture
Kymera_Images_Leadership_Headshot_Juliet-Williams-PhD
Juliet Williams, Ph.D.
Head of Research

Board of Directors

Our esteemed board comprises leaders with the experience and perspective to support Kymera’s evolution as we work to improve patients’ lives.
Nello Mainolfi, Ph.D.
Founder, President & CEO
Bruce Booth, DPhil
Chairman and Co-Founder
Jeff Albers, JD, MBA
Pamela Esposito, PhD
Joanna Horobin, MB, ChB
Gorjan Hrustanovic, PhD
John Maraganore, PhD
Leigh Morgan
Victor Sandor, MDCM
Elena Ridloff, CFA

module: m-pipeline
Pipeline

Kymera’s pipeline is focused on addressing disease targets where there is significant patient need and where we believe protein degradation is the only or best way to improve the standard of care.

Therapeutic Areas
Immunology-inflamation
Oncology
Program
Preclinical
Phase 1
Phase 2
Phase 3
Rights
Immunology Pipeline
IRAK4
KT-474/SAR444656 (AD)
KT-474/SAR444656 (HS)
Potential Indications: AD, HS
TARGET & PATHWAY
IRAK4 (KT-474/SAR444656)*

KT-474 is a potential first-in-class IRAK4 degrader in development for the treatment of immune-inflammatory diseases with significant patient need, such as hidradenitis suppurativa (HS), atopic dermatitis (AD), and potentially others. IRAK4 is a key protein of the myddosome complex that mediates signaling through IL-1 and toll-like receptors, which play a crucial role in initiating the immune response against invading pathogens. IRAK4 is a kinase that acts at the interface of the innate and adaptive immune responses with a variety of functions depending on its kinase activity and scaffolding function. Eliminating IRAK4 completely through degradation impacts both the kinase and scaffolding functions, therefore has the potential to achieve a broad, well-tolerated, anti-inflammatory effect providing a novel therapeutic approach.

Potential Indications

Atopic Dermatitis
Hidradenitis Suppurativa

kymeratx-science-and-innovation_pipeline-IRAK4
Oncology Pipeline
module: m-cards

Choose an Area of Focus

Immunology-Inflammation

We are addressing the root molecular causes of chronic inflammatory disease.

Oncology

We are generating new knowledge on how to apply TPD to both liquid and solid tumors.

Platform

Discover more about our cutting-edge toolbox of integrated approaches to accelerate the discovery and development of transformative medicines.

Targeted Protein Degradation

Our leadership in TPD is propelling novel medicines forward.

module: m-cards (title left)

Featured Perspectives

Headshot of Karen Weisbach
March 31, 2023
Driving Culture Through Values
Karen Weisbach, PHR, Head of People + Culture
Headshot of Juliet Williams
March 1, 2023
Living Our Core Values – Pioneer: Breaking new ground with a powerful new modality
Juliet Williams, PhD, Head of Research
Headshot of Brian Albarran
April 21, 2023
Small Molecules, Big Impact: Expanding the Universe of Targets
Brian Albarran, PhD, Senior Vice President, Head of Corporate Strategy
module: m-expanding-circles

We Want to Hear from You

We’re looking for like-minded people to join us on our journey to revolutionize medicine. You belong at Kymera if you are:

Value_Clean_Pioneer icon
Pioneer
We are courageous, resilient, and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
Close
Value_Orange-Circle_Pioneer icon
Pioneer
Learn More
Value_Clean_Collaborate icon
Collaborate
We value trust and transparency from everyone. Our goals are shared, our decisions data-driven, and our camaraderie genuine.
Close
Value_Orange-Circle_Collaborate icon
Collaborate
Learn More
Value_Clean_Belong icon
Belong
We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.
Close
Value_Orange-Circle_Belong icon
Belong
Learn More
module: m-earned-media
Showing 24 news results
January 4, 2024

Endpoints News: Kymera doubles down on protein degraders for immunology, chasing Dupixent and Sotyktu

Looking to further expand the reach of protein degraders beyond cancer, Kymera Therapeutics revealed two new programs Thursday morning that it hopes will compete with some of the hottest immunology drugs on the market.

Read More
December 26, 2023

Genetic Engineering & Biotechnology News: Up-to-$2B Sanofi Collaboration Pays Off for Kymera

Through a pair of recent clinical milestones, Kymera Therapeutics continues to cash in on its up-to-$2 billion collaboration with Sanofi to develop first-in-class targeted protein degradation (TPD) therapies for patients with immune-inflammatory diseases.

Read More
December 11, 2023

BioCentury: Building on dermatology’s recent success

Once cast off by most pharmas and investors, dermatology drug development is experiencing a renaissance. A standout commercial success has put atopic dermatitis on the map. Each new psoriasis therapy is extending efficacy. And emerging drug classes are promising to expand the pool of responders, both within dermatology’s major indications and into new ones.

Read More
December 4, 2023

Nature Reviews Drug Discovery: PROTAC in clinic for autoimmune skin disease

The kinase IRAK4 is a crucial regulator of signalling pathways that control innate immunity. Inhibitors of its kinase activity have been developed for autoimmune diseases but have not shown strong efficacy. Now, in Nature Medicine, Ackerman et al. describe an IRAK4 protein degrader and report encouraging preliminary results in patients with chronic inflammatory skin diseases.

Read More
November 29, 2023

Boston Globe: Top Places to Work in Massachusetts 2023

Nearly 76,000 workers at 347 companies responded to the survey questions rating their employers on leadership, values, training, benefits, and other metrics. The rankings are broken down into four size categories: small (50-99 employees); medium (100-249); large (250-999); and largest (1,000 or more).

Read More
November 28, 2023

Drug Hunter: KT-474 Brings IRAK4 Back: The First Clinically Active Bifunctional Degrader Outside Oncology

Kymera’s KT-474 is the first oral degrader to demonstrate activity in clinical trials outside cancer. Sanofi recently started a Ph. II trial with the molecule in AD, restoring life to IRAK4 as an immunology target.

Read More
November 20, 2023

Dermatology News: KT-474 Demonstrates Efficacy and Promise in Atopic Dermatitis and Hidradenitis Suppurativa Study

Kymera Therapeutics recently shared promising results from the phase 1 clinical trial of its lead program, KT-474, marking a significant milestone in the field of targeted protein degradation (TPD).

Read More
November 20, 2023

C&EN: Degrader progresses in clinical trials for skin conditions

Kymera Therapeutics’ degrader KT-474 has shown promise for treating two inflammatory skin conditions in an early clinical trial. The success suggests that these compounds could be used to treat nonlethal, chronic conditions, where there is a high bar for tolerability.

Read More
October 21, 2023

Talking Biotech: Therapeutics Controlling Protein Turnover – Dr. Juliet Williams

Cells have intricate mechanisms to remove damaged or mis-expressed proteins that could be deleterious to cellular function. This process is mediated by a process called ubiquitination, mediated by a special class of proteins called E3 ligases. Ubiquitin is the tag that’s added that signals that a protein should be moved to the biochemical garbage can. Dr. Juliet WIlliams of Kymera describes how their company has used modeling and A.I. to design molecular linkers that connect a protein that needs to be degraded with the machinery to tag it for destruction.

Read More
September 21, 2023

Watertown News: Watertown Life Science Company Entering Team in Jimmy Fund Walk

The company has a program called Kymera Cares, an effort that allows employees to give back, volunteer, and fundraise for organizations helping local communities throughout the greater Boston area as well as patients and their support systems.

Read More

CONTACT
PRESS RELEASES
COMPANY BACKGROUND
module: m-clinical-trials

KT-474 (SAR444656) is an investigational degrader in development for the treatment of immunological and inflammatory diseases

The safety and efficacy of KT-474 (SAR444656) is currently being evaluated in double blind, placebo-controlled, randomized Phase 2 clinical trials in adult patients with moderate to severe Hidradenitis Suppurativa and Atopic Dermatitis.

OPEN
Phase
Phase 2
Conditions
Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)

KT-253 is an investigational degrader in development for the treatment of solid tumors and hematological malignancies

This is an open-label Phase 1 first-in-human study of KT-253 in adult patients to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics, and clinical activity in liquid and solid tumors.

OPEN
Phase
Phase 1
Conditions
Acute Lymphocytic Leukemia, Advanced Solid Tumors, Lymphomas, Myeloid Malignancies

KT-333 is an investigational degrader in development for the treatment of solid tumors and hematological malignancies

This is an open-label Phase 1 first-in-human study of KT-333 in adult patients to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics, and clinical activity in liquid and solid tumors.

OPEN
Phase
Phase 1
Conditions
Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), Non-Hodgkin Lymphoma (NHL), Peripheral T-Cell Lymphoma (PTCL), Solid Tumors